Pharsight

1. Uptravi patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17186415A	2020-10-15	Generics [UK] Limited	Granted and Under Opposition
EP17191033A	2020-07-09	Generics (UK) Ltd	Granted and Under Opposition
EP17191033A	2020-07-09	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP17191033A	2020-07-06	Aera A/S	Granted and Under Opposition
EP10792183A	2018-09-05	Hexal AG	Granted and Under Opposition
EP10792183A	2018-09-04	Generics [UK] Ltd	Granted and Under Opposition
EP10792183A	2018-09-03	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09786912A	2018-07-25	Hexal AG	Granted and Under Opposition
EP09786912A	2018-07-24	STADA Arzneimittel AG	Granted and Under Opposition
EP09786912A	2018-07-24	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP09786912A	2018-07-23	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09786912A	2018-07-19	Generics (UK) Ltd	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7205302	ACTELION	Heterocyclic compound derivatives and medicines	Oct, 2026 (3 years from now)
US8791122	ACTELION	Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same	Aug, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881	ACTELION	Therapeutic compositions containing macitentan	Aug, 2029 (5 years from now)
US9284280	ACTELION	Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide	Jun, 2030 (6 years from now)
US10828298	ACTELION	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide	Dec, 2036 (13 years from now)
US10821108	ACTELION	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide	Dec, 2036 (13 years from now)

Market Authorisation Date: 29 July, 2021

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...

Dosage: POWDER;INTRAVENOUS